This suggests that silencing the ACC2 (a rate-limiting enzyme for de novo lipid synthesis and the inhibition of fatty acid oxidation) may contribute to BRAFV600E-inhibitor (e.g., vemurafenib) resistance and increased tumor growth. Here, ACACB is linked to neoplasm.